首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Cancer biology & medicine

缩写:

ISSN:2095-3941

e-ISSN:2095-3941

IF/分区:12.4/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引1069条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Yanna Bi,Sisi Wei,Zhe Zhang et al. Yanna Bi et al.
Objective: Paclitaxel (PTX), a conventional second-line therapeutic agent for advanced gastric cancer (GC), exhibits compromised clinical efficacy due to acquired chemoresistance in patients, the molecular mechanisms of w...
Zhengyang Bai,Dan Yang,Jiayi Li et al. Zhengyang Bai et al.
Objective: Breast cancer is the most common malignancy in women and is characterized by a high recurrence rate that severely impacts patient survival. Regulatory T cells (Tregs) in the tumor microenvironment (TME) promote...
Zijian Lv,Tiance Wang,Runjia Fan et al. Zijian Lv et al.
Objective: Clinical use of stimulator of interferon genes (STING) agonists has challenges due to poor responsiveness and variable efficacy. Therefore, identifying tumor types that are sensitive to these agents and clarify...
Yangyang Zhang,Jingli Xu,Siwei Pan et al. Yangyang Zhang et al.
In recent years the crucial role of CD4+ T cells in tumor immunomodulation has garnered increasing recognition. While conventional cancer immunotherapy research has predominantly focused on the cytotoxic function of CD8+ T cells, emerging e...
Weikang Chen,Haojie Bai,Maoling Tian et al. Weikang Chen et al.
Objective: Recent clinical evidence indicates that persistent reservoirs of SARS-CoV-2 in human brain tissue are associated with various neurologic symptoms. While brain tumors have unique vascular abnormalities and immun...
Sifan Li,Chang Che,Yelu Zhou et al. Sifan Li et al.
Anti-programmed cell death protein 1 (PD-1) or its ligand (PD-L1) are immune checkpoint inhibitors (ICIs) that have revolutionized cancer therapy. However, the efficacy of anti-PD-1 and anti-PD-L1 is limited by resistance and inter-individu...